Lung/Respiratory Conditions

Main Content

F508del Study

Study title

Phase 3, randomized, double-blind, controlled study evaluating the efficacy and safety of VX-659 in combination therapy in subjects with cystic fibrosis (CF) who are heterozygous for the F508del mutation and a minimal function mutation (F/MF)

  • Principal Investigator:  Dr. John Spurzem


This study is being conducted to evaluate the effectiveness and safety of an oral experimental medication when taken in combination with two other medications in patients with CF. This triple combination therapy is being tested to see if it improves chloride transport to help treat CF.

Who can participate

Those eligible to participate in this study include:

  • Persons at least 12 years old with CF

For more information

  • Cathy Hudgins, RN
    University of Mississippi Medical Center
    2500 N. State St.
    Jackson MS 39216
    (601) 815-9276
  • IRB Number: 2018-0059